BR0114430A - Processos para a indução da morte de células cancerìgenas e para a regressão de tumor - Google Patents

Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Info

Publication number
BR0114430A
BR0114430A BR0114430-8A BR0114430A BR0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A
Authority
BR
Brazil
Prior art keywords
cell death
cancer cell
processes
tumor regression
death induction
Prior art date
Application number
BR0114430-8A
Other languages
English (en)
Inventor
George Q Daley
Original Assignee
George Q Daley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Q Daley filed Critical George Q Daley
Publication of BR0114430A publication Critical patent/BR0114430A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PROCESSOS PARA A INDUçãO DA MORTE DE CéLULAS CANCERìGENAS E PARA A REGRESSãO DE TUMOR". São fornecidos processos para o tratamento de câncer, que compreendem a administração de (1) um inibidor da farnesila proteína transferase em associação com (2) um inibidor adicional da via de sinalização de Ras para induzir a morte de células cancerígenas e a regressão de tumores.
BR0114430-8A 2000-10-05 2001-10-05 Processos para a indução da morte de células cancerìgenas e para a regressão de tumor BR0114430A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
BR0114430A true BR0114430A (pt) 2004-01-06

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114430-8A BR0114430A (pt) 2000-10-05 2001-10-05 Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Country Status (14)

Country Link
US (1) US6777415B2 (pt)
EP (1) EP1322334A2 (pt)
JP (1) JP2004510733A (pt)
CN (1) CN1479630A (pt)
AU (2) AU1186202A (pt)
BR (1) BR0114430A (pt)
CA (1) CA2424797C (pt)
HK (1) HK1052870A1 (pt)
HU (1) HUP0302913A3 (pt)
MX (1) MXPA03003011A (pt)
NO (1) NO20031531L (pt)
NZ (1) NZ524936A (pt)
WO (1) WO2002028381A2 (pt)
ZA (1) ZA200302523B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
US20030185831A1 (en) * 2001-11-30 2003-10-02 Schering Corporation Methods of treating cancer using an FPT inhibitor and antineoplastic
CN1849122A (zh) * 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
EP1654377A4 (en) * 2002-03-01 2010-03-24 Roger Williams Hospital PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
AU2006315651A1 (en) * 2005-11-11 2007-05-24 Roger Williams Hospital P66-Shc as predictive marker in cancer treatment
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563134B1 (en) 1990-12-18 1996-06-19 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc CANCER TREATMENT METHOD
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
ATE218137T1 (de) * 1997-06-17 2002-06-15 Schering Corp Benzo(5,6)cyclohepta(1,2-b)pyridin derivate als farnesyl protein transferase inhibitoren
KR20010013881A (ko) 1997-06-17 2001-02-26 둘락 노먼 씨. 파네실 단백질 전이효소의 신규한 ｎ-치환된 우레아 억제제
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
ATE248170T1 (de) 1999-01-11 2003-09-15 Univ Princeton Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
WO2002028381A3 (en) 2003-03-27
MXPA03003011A (es) 2003-07-14
AU1186202A (en) 2002-04-15
AU2002211862B2 (en) 2007-03-15
WO2002028381A2 (en) 2002-04-11
JP2004510733A (ja) 2004-04-08
HUP0302913A3 (en) 2005-05-30
NO20031531D0 (no) 2003-04-04
US20020128280A1 (en) 2002-09-12
NO20031531L (no) 2003-06-05
HK1052870A1 (zh) 2003-10-03
EP1322334A2 (en) 2003-07-02
CN1479630A (zh) 2004-03-03
HUP0302913A2 (hu) 2003-12-29
CA2424797A1 (en) 2002-04-11
US6777415B2 (en) 2004-08-17
NZ524936A (en) 2005-08-26
ZA200302523B (en) 2004-08-24
CA2424797C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
BR0114430A (pt) Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
AR027355A1 (es) Acidos tiazolidincarboxilicos
ATE281431T1 (de) Resorcin-derivate
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
DE60230017D1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
PT1195159E (pt) Combinacao terapeutica de ascorbato com lisina e arginina para prevencao e tratamento do cancro
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
AR025885A1 (es) Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas
EA200400235A1 (ru) Комбинированная терапия для лечения рака
BR0317573A (pt) Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0213181A (pt) Combinações de inibidor de cox-2
MY137303A (en) Methods for treating proliferative diseases
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
PA8506201A1 (es) Quimioterapia de combinacion (combination chemotherapy)
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
PT980205E (pt) Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos
ES2164584A1 (es) Terapia con cannabinoides para el tratamiento de tumores cerebrales.
ECSP003417A (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
TR200302193T4 (tr) Kombinasyon kemoterapisi.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.